RoslinCT Appoints Lee Warren as Chief Financial Officer
Edinburgh, UK, 15 June 2022 – RoslinCT – a cell and gene therapy/ATMP CDMO, developing life-changing cell and gene therapies in Edinburgh’s BioQuarter – announces the appointment of Lee Warren as CFO.
Lee joined RoslinCT as CFO in April 2022, having previously spent over 7 years at Cobra Biologics, most recently as Director, Global Finance. During his time at Cobra Lee oversaw a period of rapid growth and expansion, driving significant revenue and EBITDA growth, and was involved in several M&A transactions.
“I am pleased to welcome Lee to our leadership team,” said RoslinCT CEO, Peter Coleman. “His deep and extensive experience in leading the financial operations of lifescience companies will make an major impact in our future growth and add invaluable strength to RoslinCT’s corporate initiatives. I am confident that Lee will provide strong leadership and is an excellent addition to the RoslinCT team.”
Lee is a qualified Chartered Accountant with an audit background. He has spent time in the financial services sector and also held a number of senior management positions in the mobile telecommunications sector. As CFO, Lee will lead RoslinCT’s financial activities including accounting and controllership, financial planning and analysis, tax, investor relations, internal audit, and treasury.
Lee Warren said: “I am delighted to join RoslinCT as CFO. The RoslinCT team have done a fantastic job in growing the business in recent years, and we have exciting plans for further growth and expansion in the future which are supported by GHO. I am looking forward to being part of the journey, and RoslinCT becoming a world leader in the cell and gene therapy manufacturing field.”
RoslinCT has entered a new and exciting phase of growth alongside investors, GHO Capital Partners to become a global leader in the cell & gene therapy space building on the great science, capabilities and hard work so far. Since the investment from GHO, RoslinCT has already seen tremendous growth in the company and further building of the senior team. This puts RoslinCT in an even stronger position to continue to partner with existing and new customers and provide life-changing and life-saving cell therapies for our patients.
RoslinCT is a leading UK Cell Therapy Contract Development and Manufacturing Organisation (CDMO) focused on providing services for companies developing cell-based therapeutic products. Originally founded in 2006 as a spin-out from the Roslin Institute, we built on the broad range of scientific expertise available in the field of cell biology. Based at the Edinburgh BioQuarter, we operate fully licensed GMP manufacturing facilities and have a proven track record in the delivery of cell-based products. www.roslinct.com.
About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high-growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market-leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.